title: Severe interstitial lung disease following treatment with certolizumab pegol: a case report.
authors.forename: Jakob
authors.initials: J
authors.lastname: Lager
authors.forename: Ole
authors.initials: O
authors.lastname: Hilberg
authors.forename: Anders
authors.initials: A
authors.lastname: Løkke
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Bendstrup
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011092:Polyethylene Glycols / Q000009:adverse effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol